3D Cell Culture Market by Type (Hydrogel, ECM, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharma, Biotech, Research, Cosmetics), Region - Global Forecast to 2027
The global 3D cell culture market in terms of revenue was estimated to be worth $1.3 billion in 2022 and is poised to reach $2.6 billion by 2027, growing at a CAGR of 15.6% from 2022 to 2027. Growth in this market is mainly driven by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, a lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
3D Cell Culture Market Dynamics
Drivers: Increasing focus on developing alternatives to animal testing
Animal models are widely used in cell biology research for studying human-specific diseases. However, this carries several disadvantages—the possibility of harm to animals and difficulties in ensuring result accuracy due to differences in species, disease mechanisms, and drug responses. To overcome these issues, various institutes are involved in developing alternative methods for drug development. The Directive on the Protection of Animals Used for Scientific Purposes (2010/63); the Regulation on Cosmetic Products (1223/2009); REACH (2007/2006); and Classification, Labeling, and Packaging (CLP) (1272/2008) are some European regulations that strongly encourage the replacement of animal testing. Additionally, the Canadian Centre for Alternatives to Animal Methods, the Canadian Centre for the Validation of Alternative Methods, Cruelty Free International, and the Fund for the Replacement of Animals in Medical Experiments oppose the use of animal-based models for research.
Opportunities: Emergence of microfluidics-based 3D cell culture
Recent advances have enabled microfluidics in 3D cell culture to develop microenvironments that support tissue differentiation and replicate the tissue-tissue interface, spatiotemporal chemical gradients, and mechanical microenvironments of living organs. This organ-on-a-chip model enables the study of human physiology in an organ-specific context, which allows the development of in vitro disease models and eventually serves as a replacement for animal models in drug development and toxicity testing.
Key players operating in this market are entering into partnerships and collaborations with pharmaceutical companies to strengthen their market position. This strategy enables market players to evaluate the performance of their organs-on-chips offerings in drug development and other pharmaceutical research processes. For instance, in November 2021, CN Bio entered a research collaboration focused on validating novel organ-on-a-chip infection models. In July 2021, MIMETAS and Roche collaborated to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).
Challenges: Lack of consistency in 3D cell culture products
The use of scaffold-based 3D cell cultures has extended the range of research opportunities. However, the presence of multiple growth factors in scaffolds leads to their batch-to-batch variability, which interferes with biological studies of signaling pathways and pharmacological investigations. Growth-factor-reduced scaffolds have been developed to overcome this difficulty, such as Matrigel Matrix (Corning). Although the cells grown upon scaffolds with reduced growth factors have displayed phenotypes similar to those grown upon high-growth-factor scaffolds, the proliferation rate was very high.
In addition, cells grown on low-growth-factor scaffolds cannot be approved for human implantation. This highlights the need for materials offering the natural functionality of ECM and the capability to specify biological and material properties. Scaffolds made of synthetic materials, such as synthetic peptides, are anticipated to address this obstacle soon; however, the lack of consistency will remain a key market challenge until their introduction.
The clinical research services subsegment of the type segment dominated the Contract Research Organization (CROs) Services Market in 2021
On the basis of type, the 3D cell culture market is segmented into scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures. Scaffold-based 3D cell cultures accounted for the largest share of this market in 2021. The scaffolds in 3D cell culture offer advantages such as structural rigidity, the availability of attachment points, and support, which drive the preference for scaffold-based 3D cell cultures. This in turn favored the large share of this segment.
To know about the assumptions considered for the study, download the pdf brochure
North America was the largest regional market for 3D Cell Culture Market in 2021.
North America accounted for the largest share of the global market in 2021. The increasing incidence of cancer and the well-established pharmaceutical and biotechnology industry are key factors supporting the growth of the North American market.
Key players in this market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza Group AG (Switzerland), Avantor Inc. (US), Tecan Trading AG (Switzerland), 3D Biotek LLC (US), REPROCELL Inc. (Japan), Kirkstall Ltd (UK), MIMETAS BV (Netherlands), PromoCell GmbH (Germany, Emulate Inc. (US), CN Bio Innovations (UK), InSphero AG (Switzerland), Greiner Bio-One International GmbH (Austria), TissUse GmbH (Germany), Synthecon Incorporated (US), Lena Biosciences (US), QGel SA (Switzerland), UAB Ferentis (Lithuania), Advanced BioMatrix Inc. (Part of BICO Group) (US)
3D Cell Culture Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$1.3 billion |
|
Estimated Value by 2027 |
$2.6 billion |
|
Growth Rate |
Poised to grow at a CAGR of 15.6% |
|
Largest Share Segments |
|
|
Market Report Segmentation |
Type, Application, End user, and Region |
|
Growth Drivers |
|
|
Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
3D Cell Culture Market Segmentation
By Type
- Scaffold-based 3D Cell Cultures
- Scaffold-free 3D Cell Cultures
- Microfluidics-based 3D Cell Cultures
- Magnetic & Bioprinted 3D Cell Cultures
By Application
- Cancer & Stem Cell Research
- Drug Discovery & Toxicology Testing
- Tissue Engineering & Regenerative Medicine
By End User
- Pharmaceutical & Biotechnology Companies
- Research Institutes
- Cosmetics Industry
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- China
- Japan
- India
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Middle East and Africa (MEA)
Recent Developments
- In July 2021, Lonza Group AG (Switzerland) and CN Bio Innovations (UK) announced a distribution agreement providing pre-validated hepatocytes for use on CN Bio’s innovative PhysioMimix Organ-On-a-Chip (OOC) range of single and multi-organ microphysiological systems (MPS).
- In March 2021, Thermo Fisher Scientific Inc. (US) planned to spend around USD 600 million on expanding its bioprocessing production capabilities in Americas, Europe, and Asia.
Frequently Asked Questions (FAQ):
What is the size of 3D Cell Culture Market ?
The global 3D cell culture market size is projected to USD 2.6 billion by 2027, growing at a CAGR of 15.6%.
What are the major growth factors of 3D Cell Culture Market ?
Growth in this market is mainly driven by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, a lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the forecast period.
Who all are the prominent players of 3D Cell Culture Market ?
Key players in this market includes Thermo Fisher Scientific (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza Group AG (Switzerland), Avantor Inc. (US), Tecan Trading AG (Switzerland), 3D Biotek LLC (US), REPROCELL Inc. (Japan), Kirkstall Ltd (UK), MIMETAS BV (Netherlands), PromoCell GmbH (Germany, Emulate Inc. (US), CN Bio Innovations (UK), InSphero AG (Switzerland), Greiner Bio-One International GmbH (Austria), TissUse GmbH (Germany), Synthecon Incorporated (US), Lena Biosciences (US), QGel SA (Switzerland), UAB Ferentis (Lithuania), Advanced BioMatrix Inc. (Part of BICO Group) (US) .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 30)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 34)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: 3D CELL CULTURE MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 GLOBAL MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 6 GLOBAL MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
FIGURE 7 GLOBAL MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
2.4 DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.5.1 COVID-19-SPECIFIC ASSUMPTIONS
2.6 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 45)
FIGURE 9 3D CELL CULTURE MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 GLOBAL MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 11 GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 48)
4.1 3D CELL CULTURE MARKET OVERVIEW
FIGURE 13 INCREASING FOCUS ON DEVELOPING ALTERNATIVES TO ANIMAL TESTING IS A MAJOR FACTOR DRIVING THE ADOPTION OF 3D CELL CULTURE SOLUTIONS
4.2 NORTH AMERICA: MARKET, BY TYPE AND COUNTRY (2021)
FIGURE 14 SCAFFOLD-BASED 3D CELL CULTURES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN GLOBAL MARKET IN 2021
4.3 GLOBAL MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 15 CANCER & STEM CELL RESEARCH WILL CONTINUE TO DOMINATE THE MARKET IN 2027
4.4 GLOBAL MARKET SHARE, BY END USER, 2021 (USD MILLION)
FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED THE MARKET IN 2021
4.5 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 ASIA PACIFIC COUNTRIES TO REGISTER THE HIGHEST GROWTH RATE FROM 2022 TO 2027
5 MARKET OVERVIEW (Page No. - 52)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 3D CELL CULTURE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing focus on developing alternatives to animal testing
5.2.1.2 Growing focus on personalized medicine
TABLE 1 GROWTH IN THE NUMBER OF PERSONALIZED MEDICINES
5.2.1.3 Increasing incidence of chronic diseases
TABLE 2 PREVALENCE OF DIABETES, BY REGION, 2000 VS. 2030
TABLE 3 INCIDENCE OF CANCER, BY TYPE, 2020 VS. 2040
5.2.1.4 Availability of funding for research
5.2.1.5 Growing demand for 3D cell culture
5.2.2 RESTRAINTS
5.2.2.1 Lack of infrastructure for 3D cell-based research
5.2.2.2 High cost of cell biology research
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of microfluidics-based 3D cell culture
5.2.3.2 Emerging economies
5.2.3.3 Regenerative medicine as an alternative to organ transplantation
5.2.3.4 Risk of pandemics and communicable diseases
5.2.4 CHALLENGES
5.2.4.1 Lack of consistency in 3D cell culture products
5.2.4.2 Plastic waste disposal
TABLE 4 COMPARISON OF SINGLE-USE BIOPROCESSING SYSTEM DISPOSAL OPTIONS
5.3 RANGES/SCENARIOS
FIGURE 19 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE 3D CELL CULTURE MARKET
5.4 IMPACT OF THE COVID-19 OUTBREAK ON THE GLOBAL MARKET
FIGURE 20 GLOBAL MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2020–2022
FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 PRICING ANALYSIS
TABLE 5 SELLING PRICE OF 3D CELL CULTURE PRODUCTS BY TOP PLAYERS
5.6 TECHNOLOGY ANALYSIS
TABLE 6 ADVANTAGES AND DISADVANTAGES OF 3D CELL CULTURE TECHNIQUES
TABLE 7 ADVANTAGES AND DISADVANTAGES OF 3D CELL CULTURE METHODS
5.7 PATENT ANALYSIS
FIGURE 22 PATENT APPLICATIONS FOR THE CELL CULTURE MARKET, JANUARY 2011–DECEMBER 2021
TABLE 8 INDICATIVE LIST OF PATENTS IN THE 3D CELL CULTURE MARKET
5.8 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS OF THE GLOBAL MARKET: RAW MATERIAL AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 24 GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
TABLE 9 SUPPLY CHAIN ECOSYSTEM
5.11 KEY CONFERENCES & EVENTS IN 2022–2023
TABLE 10 GLOBAL MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.12 REGULATORY ANALYSIS
5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 3D CELL CULTURE MARKET: PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS OF 3D CELL CULTURE PRODUCTS
5.14.2 BUYING CRITERIA FOR 3D CELL CULTURE PRODUCTS
FIGURE 26 KEY BUYING CRITERIA FOR END USERS
6 3D CELL CULTURE MARKET, BY TYPE (Page No. - 79)
6.1 INTRODUCTION
TABLE 16 GLOBAL MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 SCAFFOLD-BASED 3D CELL CULTURES
TABLE 17 SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 18 SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 19 NORTH AMERICA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 EUROPE: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 ASIA PACIFIC: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 HYDROGELS/ECM ANALOGS
6.2.1.1 Hydrogels/ECM analogs dominate the scaffold-based 3D cell cultures market
TABLE 22 HYDROGELS/ECM ANALOGS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 23 NORTH AMERICA: HYDROGELS/ECM ANALOGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 EUROPE: HYDROGELS/ECM ANALOGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 25 ASIA PACIFIC: HYDROGELS/ECM ANALOGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 SOLID SCAFFOLDS
6.2.2.1 Solid scaffolds are widely adopted in regenerative medicine and preclinical in vitro testing
TABLE 26 SOLID SCAFFOLDS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 27 NORTH AMERICA: SOLID SCAFFOLDS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 EUROPE: SOLID SCAFFOLDS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 ASIA PACIFIC: SOLID SCAFFOLDS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 MICROPATTERNED SURFACES
6.2.3.1 Micropatterned surfaces enhance the expression of enzymes levels and drug reactivity
TABLE 30 MICROPATTERNED SURFACES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: MICROPATTERNED SURFACES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 EUROPE: MICROPATTERNED SURFACES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 ASIA PACIFIC: MICROPATTERNED SURFACES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 SCAFFOLD-FREE 3D CELL CULTURES
TABLE 34 SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 35 SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 EUROPE: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 ASIA PACIFIC: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.1 LOW ATTACHMENT PLATES
6.3.1.1 Low attachment plates are expected to grow at the highest rate in the scaffold-free 3D cell cultures market
TABLE 39 LOW ATTACHMENT PLATES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 40 NORTH AMERICA: LOW ATTACHMENT PLATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: LOW ATTACHMENT PLATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 ASIA PACIFIC: LOW ATTACHMENT PLATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2 HANGING DROP PLATES
6.3.2.1 Hanging drop plates are widely used in stem cell differentiation and cytotoxicity research
TABLE 43 HANGING DROP PLATES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 44 NORTH AMERICA: HANGING DROP PLATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 EUROPE: HANGING DROP PLATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 46 ASIA PACIFIC: HANGING DROP PLATES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.3 3D BIOREACTORS
6.3.3.1 3D bioreactors are commonly used in the mass production of cells
TABLE 47 3D BIOREACTORS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 48 NORTH AMERICA: 3D BIOREACTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 EUROPE: 3D BIOREACTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 50 ASIA PACIFIC: 3D BIOREACTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.4 3D PETRI DISHES
6.3.4.1 Europe will witness the highest growth in the 3D Petri dishes market
TABLE 51 3D PETRI DISHES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 52 NORTH AMERICA: 3D PETRI DISHES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 EUROPE: 3D PETRI DISHES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 ASIA PACIFIC: 3D PETRI DISHES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 MICROFLUIDICS-BASED 3D CELL CULTURES
6.4.1 MICROFLUIDICS-BASED 3D CELL CULTURES WILL GROW AT THE HIGHEST RATE IN THE 3D CELL CULTURE MARKET
TABLE 55 MICROFLUIDICS-BASED 3D CELL CULTURE MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: MICROFLUIDICS-BASED MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 EUROPE: MICROFLUIDICS-BASED MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 ASIA PACIFIC: MICROFLUIDICS-BASED MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 MAGNETIC & BIOPRINTED 3D CELL CULTURES
6.5.1 3D CELL CULTURE CAN BE FORMED WITHOUT MEDIA IN MAGNETIC LEVITATION
TABLE 59 MAGNETIC & BIOPRINTED 3D CELL CULTURES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 60 NORTH AMERICA: MAGNETIC & BIOPRINTED 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 EUROPE: MAGNETIC & BIOPRINTED 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 ASIA PACIFIC: MAGNETIC & BIOPRINTED 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 3D CELL CULTURE MARKET, BY APPLICATION (Page No. - 100)
7.1 INTRODUCTION
TABLE 63 GLOBAL MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.2 CANCER & STEM CELL RESEARCH
7.2.1 RISING PREVALENCE OF CANCER IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT
TABLE 64 GLOBAL MARKET FOR CANCER & STEM CELL RESEARCH, BY REGION, 2020–2027 (USD MILLION)
TABLE 65 NORTH AMERICA: MARKET FOR CANCER & STEM CELL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 66 EUROPE: MARKET FOR CANCER & STEM CELL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 ASIA PACIFIC: MARKET FOR CANCER & STEM CELL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 DRUG DISCOVERY & TOXICOLOGY TESTING
7.3.1 INCREASING ADOPTION OF PERSONALIZED MEDICINES TO SUPPORT MARKET GROWTH
TABLE 68 3D CELL CULTURE MARKET FOR DRUG DISCOVERY & TOXICOLOGY TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & TOXICOLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 EUROPE: MARKET FOR DRUG DISCOVERY & TOXICOLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & TOXICOLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 TISSUE ENGINEERING & REGENERATIVE MEDICINE
7.4.1 INCREASING TISSUE ENGINEERING & REGENERATIVE MEDICINE RESEARCH TO DRIVE THIS MARKET
TABLE 72 3D CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2020–2027 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 ASIA PACIFIC: MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2020–2027 (USD MILLION)
8 3D CELL CULTURE MARKET, BY END USER (Page No. - 108)
8.1 INTRODUCTION
TABLE 76 GLOBAL MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF 3D CELL CULTURE PRODUCTS
TABLE 77 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 78 NORTH AMERICA: 3D CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 EUROPE: GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 RESEARCH INSTITUTES
8.3.1 INCREASING GOVERNMENT FUNDING FOR RESEARCH & HIGH PREVALENCE OF CANCER ARE DRIVING MARKET GROWTH
TABLE 81 3D CELL CULTURE MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 82 NORTH AMERICA: MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 EUROPE: MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 84 ASIA PACIFIC: MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 COSMETICS INDUSTRY
8.4.1 FOCUS ON DEVELOPING ALTERNATIVES TO ANIMAL TESTING IS A KEY FACTOR DRIVING MARKET GROWTH
TABLE 85 3D CELL CULTURE MARKET FOR THE COSMETICS INDUSTRY, BY REGION, 2020–2027 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET FOR THE COSMETICS INDUSTRY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 EUROPE: MARKET FOR THE COSMETICS INDUSTRY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 88 ASIA PACIFIC: MARKET FOR THE COSMETICS INDUSTRY, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 OTHER END USERS
TABLE 89 3D CELL CULTURE MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 90 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
9 3D CELL CULTURE MARKET, BY REGION (Page No. - 117)
9.1 INTRODUCTION
TABLE 93 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: MARKET SNAPSHOT
TABLE 94 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 NORTH AMERICA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 NORTH AMERICA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 98 NORTH AMERICA: NARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 99 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.1 US
9.2.1.1 The US dominates the North American market
TABLE 100 US: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 US: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 US: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 104 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Advancements in regenerative medicine to drive market growth in Canada
TABLE 105 CANADA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 CANADA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 107 CANADA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 109 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3 EUROPE
TABLE 110 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 111 EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 EUROPE: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 EUROPE: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 115 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Germany dominates the 3D cell culture market in Europe
TABLE 116 GERMANY: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 GERMANY: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 118 GERMANY: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 119 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 120 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.2 UK
9.3.2.1 Growth in the life sciences industry to drive market growth in the UK
TABLE 121 UK: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 UK: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 123 UK: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 124 UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 125 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Biotech industry growth supports the market in France
TABLE 126 FRANCE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 127 FRANCE: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128 FRANCE: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 129 FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 130 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Italy is a leading life science research hub in Europe
TABLE 131 ITALY: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 132 ITALY: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 133 ITALY: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 ITALY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 135 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Increasing funding from private and public organizations to aid market growth in Spain
TABLE 136 SPAIN: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 SPAIN: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 SPAIN: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 SPAIN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 140 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.6 ROE
TABLE 141 ROE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 142 ROE: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 ROE: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 144 ROE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 145 ROE: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: 3D CELL CULTURE MARKET SNAPSHOT
TABLE 146 APAC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 147 APAC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 148 APAC: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 149 APAC: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 150 APAC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 151 APAC: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Government support & strategic initiatives by key players to strengthen the biotechnology sector in China
TABLE 152 CHINA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 153 CHINA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 154 CHINA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 155 CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 156 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Rising cancer rate, growing geriatric population, and subsequent rise in healthcare spending to drive the market growth
TABLE 157 JAPAN: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 JAPAN: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 JAPAN: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 160 JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 161 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Growth in the life sciences industry to support market growth in India
TABLE 162 INDIA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 INDIA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 164 INDIA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 165 INDIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 166 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.4 ROAPAC
TABLE 167 ROAPAC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 ROAPAC: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169 ROAPAC: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 170 ROAPAC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 171 ROAPAC: MARKET, BY END USER, 2020–2027 (USD MILLION).
9.5 LATIN AMERICA
9.5.1 RISING CANCER RATE AND GROWING SUPPORT FOR RESEARCH TO DRIVE MARKET GROWTH
TABLE 172 LATIN AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 173 LATIN AMERICA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 LATIN AMERICA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 175 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 176 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 INCREASING FUNDING AND PARTNERSHIPS IN RESEARCH TO SUPPORT MARKET GROWTH
TABLE 177 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 178 MIDDLE EAST & AFRICA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 179 MIDDLE EAST & AFRICA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 180 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 181 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 162)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 29 KEY DEVELOPMENTS IN THE 3D CELL CULTURE MARKET, 2019–2022
10.3 MARKET SHARE ANALYSIS
FIGURE 30 GLOBAL MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021
TABLE 182 GLOBAL MARKET: DEGREE OF COMPETITION
10.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 31 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE GLOBAL MARKET, 2019–2021
10.5 COMPANY EVALUATION QUADRANT
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 32 MARKET: COMPANY EVALUATION QUADRANT, 2021
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 33 GLOBAL MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021
10.7 COMPANY FOOTPRINT ANALYSIS
10.7.1 COMPANY PRODUCT FOOTPRINT
TABLE 183 COMPANY PRODUCT FOOTPRINT: GLOBAL MARKET (2021)
10.7.2 COMPANY REGIONAL FOOTPRINT
TABLE 184 COMPANY REGIONAL FOOTPRINT: GLOBAL MARKET (2021)
10.7.3 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 185 GLOBAL MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 186 MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
10.8 COMPETITIVE SCENARIO
TABLE 187 PRODUCT LAUNCHES
TABLE 188 DEALS
TABLE 189 OTHER DEVELOPMENTS
11 COMPANY PROFILES (Page No. - 178)
11.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 190 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 34 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
11.1.2 MERCK KGAA
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2021)
11.1.3 CORNING INCORPORATED
TABLE 192 CORNING INCORPORATED: BUSINESS OVERVIEW
FIGURE 36 CORNING INCORPORATED: COMPANY SNAPSHOT (2021)
11.1.4 LONZA GROUP AG
TABLE 193 LONZA GROUP AG: BUSINESS OVERVIEW
FIGURE 37 LONZA GROUP AG: COMPANY SNAPSHOT (2020)
11.1.5 TECAN TRADING AG
TABLE 194 TECAN TRADING AG: BUSINESS OVERVIEW
FIGURE 38 TECAN TRADING AG: COMPANY SNAPSHOT (2021)
11.1.6 AVANTOR, INC.
TABLE 195 AVANTOR, INC.: BUSINESS OVERVIEW
FIGURE 39 AVANTOR, INC: COMPANY SNAPSHOT (2021)
11.1.7 REPROCELL INC.
TABLE 196 REPROCELL: BUSINESS OVERVIEW
11.1.8 3D BIOTEK LLC
TABLE 197 3D BIOTEK LLC: BUSINESS OVERVIEW
11.1.9 EMULATE, INC.
TABLE 198 EMULATE, INC.: BUSINESS OVERVIEW
11.1.10 CN BIO INNOVATIONS LIMITED
TABLE 199 CN BIO INNOVATIONS LIMITED: BUSINESS OVERVIEW
11.1.11 SYNTHECON, INCORPORATED
TABLE 200 SYNTHECON, INCORPORATED: BUSINESS OVERVIEW
11.1.12 INSPHERO AG
TABLE 201 INSPHERO AG: BUSINESS OVERVIEW
11.1.13 KIRKSTALL LTD.
TABLE 202 KIRKSTALL LTD.: BUSINESS OVERVIEW
11.1.14 MIMETAS BV
TABLE 203 MIMETAS BV: BUSINESS OVERVIEW
11.1.15 TISSUSE GMBH
TABLE 204 TISSUSE GMBH: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS
11.2.1 HAMILTON COMPANY
11.2.2 QGEL SA
11.2.3 LENA BIOSCIENCES
11.2.4 CELLENDES GMBH
11.2.5 UAB FERENTIS
11.2.6 GREINER BIO-ONE INTERNATIONAL GMBH
11.2.7 PROMOCELL GMBH
11.2.8 ADVANCED BIOMATRIX, INC. (PART OF BICO GROUP)
11.2.9 VISIKOL, INC. (FORMERLY HUREL CORPORATION)
11.2.10 SYNVIVO INC.
12 APPENDIX (Page No. - 224)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information to analyze the global 3D cell culture market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from government sources, such as the World Health Organization (WHO), American Society for Cell Biology (ASCB), American Society for Gene and Cell Therapy (ASGCT), Centers of Disease Control and Prevention (CDC), and Japan Agency for Medical Research and Development. Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global 3D cell culture market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as personnel from pharmaceutical and biopharmaceutical industries, CDMOs and CROs, academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across four major regions, including North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
3D Cell Culture Market Size Estimation
The global size of the 3D cell culture market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive primary and secondary research.
- The revenues generated from the 3D cell culture business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Report Objectives
- To define, describe, and forecast the 3D cell culture market based on product, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall 3D cell culture market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East & Africa (MEA)
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, funding and grants, partnerships, agreements, collaborations, expansions, strategic alliances, and acquisitions in the market
- To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report
Growth opportunities and latent adjacency in 3D Cell Culture Market
How the leading companies are dominating the Global 3D Cell Culture Market?
Which of the segment is expected to grab the largest share of the global 3D Cell Culture Market?
I need more details on the market growth influencing factors for the global 3D Cell Culture Market. Thank You